New chemotherapy regimen for pediatric Hodgkin lymphoma
Posted 08-19-2009 at 02:39 PM by admin
AJHO: The American Journal of Hematology/Oncology
August 18, 2009
● RESEARCHERS OF THE CHILDREN'S ONCOLOGY GROUP HAVE DEVELOPED a new chemotherapy regimen known as ABVE-PC to treat patients with pediatric Hodgkin lymphoma (HL). Led by Cindy Schwartz, MD, director of pediatric hematology/ oncology at Hasbro Children's Hospital in Providence, Rhode Island, the group combined six different drugs into a dose-dense regimen that achieves rapid early response and limits cumulative doses of the individual drugs, thereby limiting long-term toxicity.
Dr Schwartz reported, “For decades, the chemotherapy regimens known as MOPP [mechlorethamine, vincristine, procarbazine, and prednisone] and ABVD [doxorubicin, bleomycin, vinblastine, and dacarbazine] had been the standard treatment options for these patients. However, while they yielded excellent survival rates, they often resulted in long-term effects from toxicity, including infertility, second malignancy, and cardiopulmonary toxicity. With the new treatment paradigm we've developed, in essence, we've been able to cure the cancer while reducing the risk of long-term effects on our patients.”
Between 1997 and 2001, 216 eligible patients younger than 22 years with intermediate- or high-risk HL were treated with ABVE-PC (doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide). The median time from the beginning of the first cycle to the end of the third cycle was approximately 8.7 weeks, and time to completion of the fifth cycle was approximately 16 weeks. Rapid early response was documented in 63% of patients. Dose densities were greater than those of the most commonly used regimens, but cumulative doses were significantly lower, especially in the rapid responders.
According to Dr Schwartz, “This study has shown conclusively that the new chemotherapeutic treatment of ABVE-PC simultaneously provides high efficacy and reduces the cumulative doses of chemotherapy and radiation. We believe this represents a significant advance in the treatment of HL.”
Source: http://www.lifespan.org/news/2009/07...ng-term-risks/.
From the August 2009 Issue of AJHO
August 18, 2009
● RESEARCHERS OF THE CHILDREN'S ONCOLOGY GROUP HAVE DEVELOPED a new chemotherapy regimen known as ABVE-PC to treat patients with pediatric Hodgkin lymphoma (HL). Led by Cindy Schwartz, MD, director of pediatric hematology/ oncology at Hasbro Children's Hospital in Providence, Rhode Island, the group combined six different drugs into a dose-dense regimen that achieves rapid early response and limits cumulative doses of the individual drugs, thereby limiting long-term toxicity.
Dr Schwartz reported, “For decades, the chemotherapy regimens known as MOPP [mechlorethamine, vincristine, procarbazine, and prednisone] and ABVD [doxorubicin, bleomycin, vinblastine, and dacarbazine] had been the standard treatment options for these patients. However, while they yielded excellent survival rates, they often resulted in long-term effects from toxicity, including infertility, second malignancy, and cardiopulmonary toxicity. With the new treatment paradigm we've developed, in essence, we've been able to cure the cancer while reducing the risk of long-term effects on our patients.”
Between 1997 and 2001, 216 eligible patients younger than 22 years with intermediate- or high-risk HL were treated with ABVE-PC (doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide). The median time from the beginning of the first cycle to the end of the third cycle was approximately 8.7 weeks, and time to completion of the fifth cycle was approximately 16 weeks. Rapid early response was documented in 63% of patients. Dose densities were greater than those of the most commonly used regimens, but cumulative doses were significantly lower, especially in the rapid responders.
According to Dr Schwartz, “This study has shown conclusively that the new chemotherapeutic treatment of ABVE-PC simultaneously provides high efficacy and reduces the cumulative doses of chemotherapy and radiation. We believe this represents a significant advance in the treatment of HL.”
Source: http://www.lifespan.org/news/2009/07...ng-term-risks/.
From the August 2009 Issue of AJHO
Total Comments 0
Comments
Recent Blog Entries by admin
- Research and Markets: Market of Paclitaxel Injection in China (08-20-2010)
- Relief for cancer patients may be 2,000 years old (08-20-2010)
- Melanoma Research Alliance Announces $5.2 Million in New Grants (08-20-2010)
- Melanoma Research Alliance Announces $5.2 Million in New Grants to Support Six Innova (08-20-2010)
- Breast cancer survivors don't need to be afraid of air travel: U of A study (08-20-2010)
